He will continue to fight for more federal funding to combat opioids, including education, prevention, and treatment programs.

...will continue to fight for more funds for education, prevention, and treatment programs.

Promises ongoing advocacy for more opioid-response funding.

ISSUES | Andyharris
campaign · campaign_site · model gpt-5.4-mini

The homepage says the office is in the congressional primary blackout period through June 23, 2026, but that regular website updates and constituent services will continue. It also links a FY2027 Programmatic Appropriations Form and lists June 16, 2026 as the latest news item.

Current official site activity shows Harris is still engaged in appropriations-related work, but there is no opioid-specific funding action in the last three days; the promise remains unresolved.

unresolved same_term

Congressman Andy Harris |Representing the First District of Maryland
primary · model gpt-5.4-mini · confidence 65%

The committees page says Harris serves on the House Appropriations Committee and its Labor, Health and Human Services, Education, and Related Agencies subcommittee.

He still sits on the committee that controls federal health spending, so the promise is still within his federal role, but this is context rather than proof of delivered opioid funding.

unresolved same_term

Committees | Congressman Andy Harris
secondary · model gpt-5.4-mini · confidence 82%

Harris's official committees page says he serves on House Appropriations and on the Labor, Health and Human Services, Education, and Related Agencies subcommittee.

Harris has a current appropriations role directly relevant to HHS opioid prevention, treatment, and research funding, but committee membership alone does not prove that he secured or advanced more opioid funding.

unresolved same_term

Committees | Congressman Andy Harris
secondary · model gpt-5.5 · confidence 86%

Harris's press-release index says he applauded an HHS award of $2,715,203 to Salisbury-based AKYSO Therapeutics LLC for research on a new opioid use disorder treatment.

A federal HHS opioid-use-disorder research award reached Harris's district during the current term, but the official text says he applauded the award rather than showing that he requested, authored, or secured it.

partial same_term

Press Releases | Congressman Andy Harris
primary · model gpt-5.5 · confidence 78%

NIH says the HEAL Initiative is congressionally funded and works to improve prevention and treatment strategies for opioid misuse and addiction and pain management.

This confirms ongoing federal opioid-related research funding in the relevant policy area, but it does not connect the funding to Harris's own actions in the current term.

unresolved same_term

HEAL Initiative | National Institutes of Health (NIH)
secondary · model gpt-5.5 · confidence 82%

NIH lists active HEAL funding opportunities for substance use disorder and overdose interventions, prevention, recovery services, implementation, and health services research.

The federal government continued to offer opioid and substance-use research funding opportunities as of June 2026, but the page does not identify Harris as advancing those funds.

unresolved same_term

HEAL Funding Opportunities | National Institutes of Health (NIH)
secondary · model gpt-5.5 · confidence 80%

SAMHSA's State Opioid Response NOFO listed $1,480,500,000 in anticipated available funding for opioid misuse, OUD, overdose, prevention, treatment, harm reduction, and recovery services.

This is direct evidence of large federal funding for opioid prevention, treatment, and recovery programs during the relevant period, but it does not show a Harris-specific funding increase or legislative push.

partial same_term

State Opioid Response Grants | SAMHSA
secondary · model gpt-5.5 · confidence 84%

The enacted FY2024 Labor-HHS division funded substance abuse prevention at $236,879,000 and included opioid-related NIH transfer authority and State Opioid Response Grants language.

Congress enacted opioid- and substance-abuse-related funding and authorities in FY2024, but this source by itself does not establish Harris's support or role in increasing those funds.

partial same_term

Public Law 118-47, Further Consolidated Appropriations Act, 2024
secondary · model gpt-5.5 · confidence 78%

The Clerk records the House vote on H.Res.1102 for concurrence in the Senate amendment to H.R.2882 as passed, and records Harris, Republican of Maryland, voting Nay.

Harris voted against the final House vehicle for the FY2024 appropriations law that contained opioid- and substance-abuse-related funding, which weakens a finding that he delivered more opioid funding through that enacted bill.

never same_term

Office of the Clerk, U.S. House of Representatives, Roll Call 102
secondary · model gpt-5.5 · confidence 86%